Bio News
First federal jury verdict holding a pharmaceutical company liable in a “pay-for-delay” lawsuit Damages could increase to as much as $3.6 billion under antitrust law

Takeda lost a lawsuit over the delayed launch of a generic version of the constipation drug Amitiza and was ordered to pay $885 million, or approximately $1.28 billion. The jury found Takeda liable for conspiring with a competitor to delay the generic launch until 2021. Damages could increase by as much as threefold under antitrust law, and Takeda plans to appeal.

BIOBOOK TEAM
biobookmedia@biobook.co.krInflammation Gene Expression Rises Up to 3.7-Fold in Miniature Pig Intestine
Daewoong Pharmaceutical’s Flodicitinib Achieves More Than 90% Target Occupancy in Phase 1 Trial
Aribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%